1 |
Tsong Y, Chang WJ, Dong X, and Tsou HH (2012). Assessment of regional treatment effect in a multi-regional clinical trial, Journal of Biopharmaceutical Statistics, 22, 1019-1036.
DOI
|
2 |
Tsou HH, Chow SC, Lan KKG, et al. (2010). Proposals of statistical consideration to evaluation of results for a specific region in multi-regional trials - Asian perspective, Pharmaceutical Statistics, 9, 201-206.
DOI
|
3 |
Tsou HH, Hung HMJ, Chen YM, Huang WS, Chang WJ, and Hsiao CF (2012). Establishing consistency across all regions in a multi-regional clinical trial, Pharmaceutical Statistics, 11, 295-299.
DOI
|
4 |
Uesaka U (2009). Sample size allocation to regions in a multi-regional trial, Journal of Biopharmaceutical Statistics, 19, 580-594.
DOI
|
5 |
Chen J, Quan H, Binkowitz B, Quyang SP, Tanaka Y, Li G, Menjoge S, and Ibia E (2010). Assessing consistent treatment effect in a multi-regional clinical trial: a systematic review, Pharmaceutical Statistics, 9, 242-253.
DOI
|
6 |
Chen J, Quan H, Gallo P, et al. (2011). Consistency of treatment effect across regions in multi-regional clinical trials, part 1: design considerations, Drug Information Journal, 45, 595-602.
DOI
|
7 |
Chen X, Lu N, Nair R, Xu Y, Kang C, Huang Q, Li N, and Chen H (2012a). Decision rules and associated sample size planning for regional approval utilizing multi-regional clinical trials, Journal of Biopharmaceutical Statistics, 22, 1001-1018.
DOI
|
8 |
Chen CT, Hung HMJ, and Hsiao CF (2012b). Design and evaluation of multi-regional trials with heterogeneous treatment effect across regions, Journal of Biopharmaceutical Statistics, 22, 1037-1050.
DOI
|
9 |
International Conference on Harmonization (2006). Q&A for ICH E5 Guideline on Ethnic Factors in the Acceptability of Foreign Data.
|
10 |
Quan H, Li M, Chen J, et al. (2010a). Assessment of consistency of treatment effects in multiregional clinical trials, Drug Information Journal, 44, 617-632.
DOI
|
11 |
International Conference on Harmonization (2017). General Principles for Planning and Design of Multi-Regional Clinical Trials.
|
12 |
Kawai N, Chung-Stein C, Komiyama O, and Li Y (2008). An approach to rationalize partitioning sample size into individual regions in a multi-regional trial, Drug Information Journal, 42, 139-147.
DOI
|
13 |
Ko FS, Tsou HH, Liu JP, and Hsiao CF (2010). Sample size determination for a specific region in a multi-regional trial, Journal of Biopharmaceutical Statistics, 24, 870-885.
|
14 |
Liu JP, Chow SC, and Hsiao CF (2013). Design and Analysis of Bridging Studies, CRC Press, Boca Raton, FL.
|
15 |
Ministry of Health, Labor, and Welfare of Japan (2007). Basic Principles on Global Clinical Trials, from: http://www.pmda.go.jp/english/service/pdf/notications/0928010-e.pdf
|
16 |
Hung HMJ, Wang SJ, and O'Neill RT (2010). Consideration of regional difference in design and analysis of multi-regional trials, Pharmaceutical Statistics, 9, 173-178.
DOI
|
17 |
Ikeda K and Bretz F (2010). Sample size and proportion of Japanese patients in multi-regional trials, Pharmaceutical Statistics, 9, 207-216.
DOI
|
18 |
Quan H, Mao X, Chen J, Shih WJ, Ouyang SP, Zhang J, Zhao PL, and Binkowitz B (2014). Multi-regional clinical trial design and consistency assessment of treatment effects, Statistics in Medicine, 33, 2191-2205.
DOI
|
19 |
Quan H, Zhao PL, Zhang J, Roessner M, and Aizawa K (2010b). Sample size considerations for Japanese patients in a multi-regional trial based on MHLW guidance, Pharmaceutical Statistics, 9, 100-112.
|
20 |
Quan H, Li M, Shih WJ, Ouyang SP, Chen J, Zhang J, and Zhao P (2013). Empirical shrinkage estimator for consistency assessment of treatment effects in MRCT, Statistics in Medicine, 32, 1691-1706.
DOI
|